Innovent Secures Positive CHMP Opinion Recommending Zybrivo® sintilimab for First-Line Non-squamous Non-Small Cell Lung Cancer Treatment
The opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is Innovent's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe